Breaking News, Collaborations & Alliances

Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate

REX-001 is an autologous multi-cell therapy in development for the treatment of chronic limb-threatening ischemia in patients with diabetes.

Author Image

By: Charlie Sternberg

Associate Editor

Ixaka Ltd, an integrated cell and gene therapy company, and Minaris Regenerative Medicine GmbH, a contract development and manufacturing service provider for the cell and gene therapy industry, have signed an agreement to enable technology transfer as well as clinical and commercial manufacture of REX-001, Ixaka’s lead autologous multi-cell therapy (MCT) being developed for the treatment of chronic limb-threatening ischemia (CLTI) in patients with diabetes.   Under the terms of agreement, Mina...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters